Advertisement
News
Advertisement

100,000th Patient Treated With Accuray's CyberKnife® Robotic Radiosurgery System

Wed, 10/06/2010 - 5:34am
Bio-Medicine.Org

SUNNYVALE, Calif., Oct. 6 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that the 100,000th patient has been treated with the CyberKnife® Robotic Radiosurgery System, a non-invasive alternative to surgery for the treatment of both cancerous and non-cancerous tumors anywhere in the body. One in four patients treated with CyberKnife radiosurgery received treatment during Accuray's fiscal 2010, which ran July 2009 to June 2010.

Over the past five years, the average growth rate for intracranial applications, including brain tumors, arteriovenous malformations and acoustic neuromas, was 42 percent worldwide. Despite this growth, it is extracranial applications that have become the mainstay of CyberKnife usage, representing more than 50 percent of CyberKnife treatments worldwide during Accuray's fiscal 2010. The CyberKnife System is the leading radiosurgery system capable of delivering both intracranial and extracranial treatments.

Because it is also the only system that continuously tracks and automatically corrects for patient and tumor motion anywhere in the body, the CyberKnife System continues to see growth in treatments of lung and prostate cancer. The average worldwide growth rate over the past five years for CyberKnife lung treatments was 80 percent and prostate treatments was 113 percent. This strong and sustained growth demonstrates clinicians' increasing recognition of the System's unique benefits in treating tumors that move throughout treatment with respiration or other bodily functions.

"We are excited about the continued momentum and overall growth in CyberKnife adoption and usage over the past few years. With a 25 percent increase in patient treatments during our fiscal 2010 on top of an increasing base of procedures, CyberKnife radiosurgery is growing at an exponential rat

'/>"/>

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading